HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR mutant lung cancers that lack the second-site EGFR T790M mutation

Ítems similars

• Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation
  per: Oxnard, Geoffrey R., et al.
  Publicat: (2010)
• Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing
  per: Yu, H. A., et al.
  Publicat: (2014)
• Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
  per: Oxnard, Geoffrey R., et al.
  Publicat: (2011)
• Germline EGFR T790M mutation found in multiple members of a familial cohort
  per: Yu, Helena A., et al.
  Publicat: (2014)
• Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer With and Without T790M Mutations
  per: Janjigian, Yelena Y., et al.
  Publicat: (2014)